StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alexion (ALXN) Soliris IPR Surprising, But Long-Term Impact 'Limited' - Raymond James
August 30, 2019 10:59 AM
Raymond James analyst Steven Seedhouse weighed in on Alexion Pharmaceuticals (NASDAQ: ALXN) after the PTAB decided to institute an inter ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Stifel Reiterates Hold Rating on Alexion Pharmaceuticals (ALXN)
August 30, 2019 12:14 PM
Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133
August 30, 2019 12:00 PM
Piper Jaffray Defends Alexion Pharmaceuticals (ALXN)
August 30, 2019 10:44 AM
Alexion Pharmaceuticals (ALXN) PTAB News an 'Incremental Negative' - Baird
August 30, 2019 10:25 AM
Increasing unusual option volume: ALXN COO ULTA DELL AMBA
August 30, 2019 10:04 AM
Pre-Open 08/30: (SEAC) (AMBA) (MSGN) Higher (ULTA) (AOBC) (ALXN) Lower (more...)
August 30, 2019 9:19 AM
Alexion Pharma (ALXN) Soliris patents get review on Amgen (AMGN) challenge at patent office - Bloomberg
August 30, 2019 8:49 AM
